Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Eli Lilly (LLY) recently collaborated with Superluminal Medicines to advance therapeutics targeting cardiometabolic diseases, ...

(Reuters) -Superluminal Medicines said on Thursday it had signed a deal with U.S. drugmaker Eli Lilly worth up to $1.3 ...

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

In a move poised to shake the pharmaceutical landscape, Eli Lilly & Co. has inked a deal worth up to $1.3 billion with ...

The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new ...

Oracle (ORCL) stock is in focus on reports that the company will cut jobs in its cloud division — part of a broader push to ...

Eli Lilly (LLY) has entered into a deal worth up to $1.3 billion with drug discovery company Superluminal Medicines to ...

Today, I am pleased to be able to give an example of superluminal experiments done right. In work published in Physical Review A, a group of researchers from NIST and the Wuhan Institute of ...

On the other hand, I would be delighted by robust experimental results on superluminal (or lack of) group velocities, and I hope they are planning a follow-up paper.